Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Strata Critical Medical (SRTA) Cost of Revenue (2021 - 2025)

Historic Cost of Revenue for Strata Critical Medical (SRTA) over the last 5 years, with Q3 2025 value amounting to $37.7 million.

  • Strata Critical Medical's Cost of Revenue rose 3197.45% to $37.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $237.0 million, marking a year-over-year increase of 4813.36%. This contributed to the annual value of $189.8 million for FY2024, which is 366.88% up from last year.
  • Strata Critical Medical's Cost of Revenue amounted to $37.7 million in Q3 2025, which was up 3197.45% from $53.1 million recorded in Q2 2025.
  • In the past 5 years, Strata Critical Medical's Cost of Revenue registered a high of $103.9 million during Q4 2024, and its lowest value of $7.8 million during Q1 2021.
  • In the last 5 years, Strata Critical Medical's Cost of Revenue had a median value of $37.7 million in 2025 and averaged $37.9 million.
  • As far as peak fluctuations go, Strata Critical Medical's Cost of Revenue skyrocketed by 20595.43% in 2022, and later plummeted by 4888.57% in 2024.
  • Quarter analysis of 5 years shows Strata Critical Medical's Cost of Revenue stood at $20.7 million in 2021, then skyrocketed by 60.37% to $33.2 million in 2022, then rose by 16.01% to $38.5 million in 2023, then soared by 170.15% to $103.9 million in 2024, then plummeted by 63.74% to $37.7 million in 2025.
  • Its last three reported values are $37.7 million in Q3 2025, $53.1 million for Q2 2025, and $42.3 million during Q1 2025.